1. Venetoclax is safe and efficacious in relapsed/refractory AML.
- Author
-
Ganzel, Chezi, Ram, Ron, Gural, Alexander, Wolach, Ofir, Gino-Moor, Sharon, Vainstein, Vladimir, Nachmias, Boaz, Apel, Arie, Koren-Michowitz, Maya, Pasvolsky, Oren, Yerushalmi, Ronit, Danylesko, Ivetta, Cohen, Yosef, Peretz, Galit, Moshe, Yakir, Zektser, Miri, Yeganeh, Shay, Rowe, Jacob M., and Ofran, Yishai
- Subjects
ACUTE myeloid leukemia ,PLATELET count ,BONE marrow examination - Abstract
Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF